PTPRZ1 and central nervous system cancer: One must be cautious that, compared with PTPRZ in glioma cell lines, sPTPRZ in the CSF of glioma patients is heavily glycosylated, and most of the commercially available anti-PTPRZ antibodies are unable to detect CSF sPTPRZ.